Muhammad Mosaraf Hossain, PhD
Associate Professor, Department of Biochemistry & Molecular Biology
University of Chittagong
Principal Investigator (Cancer Science) and Lab Head,
EuGEF Research Group
Dr. Muhammad Mosaraf Hossain is an Associate Professor of Biochemistry & Molecular Biology, University of Chittagong (BMBCU) since 2018. Before that he joined as a Lecturer in the same university in 2011 and was upgraded to Assistant professor in 2012. He has awarded his PhD degree from NUI Galway, Ireland with College of Medicine Nursing and Health Sciences (CMNHS) scholarship for tenure of four years from 2014 to 2018. Earlier, he has completed his four years undergraduate and one year Master of Science (MS) courses from University of Chittagong major in Biochemistry & Molecular Biology securing top positions with good score in grading system. Currently, Dr. Hossain is continuing research in the field of breast cancer biology as a Principal Investigator (Cancer Science) of the Laboratory of Eukaryotic Gene Expression and Function (EuGEF Lab), BMBCU. At present his research is focusing on the role of Sonic hedgehog (Shh) and/or different miRNA (miR-4726, miR-424, Mir-17-92) in the progression of breast cancer which could be a potential therapeutic target to get additional benefit in the management of breast cancer. He received several research grants from national and international funding agencies including The World Academy of Science (TWAS), Bangladesh Medical Research Council (BMRC), University Grants Commission (UGC) and Chittagong University Research and Publication office. He presented his key research findings at reputed local and international conferences including San Antonio Breast Cancer Symposium (SABCS), Irish Association of Cancer Research (IACR) conferences, Bangladesh Society for Biochemistry & Molecular Biology (BSBMB) and Bangladesh Academy of Sciences (BAS) conferences. Dr. Hossain has published more than twenty five original research articles in reputed journals including Cell Death and Diseases, Cancer Treatment & Research Communication, Oncogene, Oncotarget, Scientific Reports etc. He is a life member of American Society for Microbiology (ASM), member of European Association of Cancer Research (EACR) and Irish Association of Cancer Research (IACR) and Bangladesh Society for Biochemistry & Molecular Biology (BSBMB).
Hossain MM, Sultana A, Barua D, Islam MN, Gupta A, Gupta S. Differential expression, function and prognostic value of miR-17-92 cluster in ER-positive and triple-negative breast cancer. Cancer Treat Res Commun. 2020 Oct 17;25:100224. doi: 10.1016/j.ctarc.2020.100224. [Epub ahead of print] PubMed PMID: 33096318.
Noman ASM, Parag RR, Rashid MI, Islam S, Rahman MZ, Chowdhury AA, Sultana A, Jerin C, Siddiqua A, Rahman L, Nayeem J, Akther S, Baidya S, Shil RK, Rahman M, Shirin A, Mahmud R, Hossain SMI, Sumi SA, Chowdhury A, Basher SB, Hasan A, Bithy S, Aklima J, Chowdhury N, Hasan MN, Banu T, Chowdhury S, Hossain MM, Yeger H, Farhat WA, Islam SS. Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation. Cell Death Dis. 2020 Aug 20;11(8):663. doi: 10.1038/s41419-020-02907-x. PubMed PMID: 32814771; PubMed Central PMCID: PMC7438524.
Hossain MM, Barua D, Arabkari V, Islam N, Gupta A, Gupta S. Hyperactivation of nuclear receptor coactivators induces PERK-dependent cell death. Oncotarget. 2018 Feb 20;9(14):11707-11721. doi: 10.18632/oncotarget.24451. eCollection 2018 Feb 20. PubMed PMID: 29545931; PubMed Central PMCID: PMC5837751.
Gupta A, Hossain MM, Miller N, Kerin M, Callagy G, Gupta S. NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK-eIF2α-ATF4 signalling in breast cancer. Oncogene. 2016 Nov 10;35(45):5860-5871. doi: 10.1038/onc.2016.121. Epub 2016 Apr 25. PubMed PMID: 27109102; PubMed Central PMCID: PMC4979996.
S Gupta, A Gupta, MM Hossain, G Callagy, K Michael. XBP1 modulates luminal breast cancer by transcriptional regulation of SRC-3 during estrogen signaling. European Journal of Cancer 2016 61; S1: S166. DOI: 10.1016/S0959-8049(16)61586-1.